Ublituximab Clinical Trials
8 recruitingDrug
Phase 42Phase 32Early Phase 11Phase 21Not Applicable1
Showing 1–8 of 8 trials
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled47 locationsNCT05877963
Recruiting
Phase 4
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Multiple Sclerosis
Johns Hopkins University50 enrolled1 locationNCT07389590
Recruiting
Not Applicable
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Multiple Sclerosis (MS) - Relapsing-remitting
University of Maryland, Baltimore30 enrolled1 locationNCT06864936
Recruiting
Phase 2
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Autoimmune Disorders
National Institute of Allergy and Infectious Diseases (NIAID)30 enrolled8 locationsNCT07103746
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.360 enrolled42 locationsNCT07211633
Recruiting
Phase 4
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting
Northwestern University40 enrolled1 locationNCT07225361
Recruiting
Early Phase 1
Effects of Ublituximab on Motor Functions in Multiple Sclerosis
Multiple Sclerosis (MS) - Relapsing-remitting
Georgia State University25 enrolled2 locationsNCT06629428
Recruiting
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Neurology Center of New England P.C.20 enrolled1 locationNCT06681623